Log In or Register to Join The Conversation!
  • This topic is empty.
Viewing 0 reply threads
  • Author
    Posts
    • #19215
      Marta Ribeiro
      Keymaster

      Overall, first-line use of Genentech’s Ocrevus for MS patients has remained stable through 2019 compared to 2018, according to Spherix Global Insights. Read more here.

      What do you think of this information?

Viewing 0 reply threads
  • You must be logged in to reply to this topic.
Copyright © 2017-2020 All rights reserved.

©2020 KLEO Template a premium and multipurpose theme from Seventh Queen

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending
or

Log in with your credentials

or    

Forgot your details?

or

Create Account